Suppression of Wnt/β-catenin signaling inhibits prostate cancer cell proliferation
- 9 November 2008
- journal article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 602 (1), 8-14
- https://doi.org/10.1016/j.ejphar.2008.10.053
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Sulindac suppresses β-catenin expression in human cancer cellsEuropean Journal of Pharmacology, 2008
- R‐spondin1 synergizes with Wnt3A in inducing osteoblast differentiation and osteoprotegerin expressionFEBS Letters, 2008
- Inactivation of Apc in the Mouse Prostate Causes Prostate CarcinomaCancer Research, 2007
- Regression of Mouse Prostatic Intraepithelial Neoplasia by Nonsteroidal Anti-inflammatory Drugs in the Transgenic Adenocarcinoma Mouse Prostate ModelClinical Cancer Research, 2004
- Lower levels of nuclear β‐catenin predict for a poorer prognosis in localized prostate cancerInternational Journal of Cancer, 2004
- WNT and β-catenin signalling: diseases and therapiesNature Reviews Genetics, 2004
- Up‐regulation of Wnt‐1 and β‐catenin production in patients with advanced metastatic prostate carcinomaCancer, 2004
- SAFETY AND EFFICACY OF EXISULIND FOR TREATMENT OF RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMYJournal of Urology, 2001
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblastsOncogene, 1998